

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-B01D3BC7-9A68-4A88-80AC-BE965F2F6B78_1_en-US
DOI: https://doi.org/10.31003/USPNF_M53673_01_01
DOI Ref: b2dam

© 2025 USPC
Do not distribute

Metronidazole Gel

DEFINITION
Metronidazole Gel contains NLT 90.0% and NMT 110.0% of the labeled amount of metronidazole ($C_6H_9N_3O_3$).

- IDENTIFICATION**
- **A.** The UV spectrum of the metronidazole peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
 - **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

- **PROCEDURE**
Solution A: Methanol and water (20:80)
Solution B: Methanol
Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	100	0
10.0	100	0
15.0	10	90
15.1	100	0
20.0	100	0

System suitability solution: 0.6 µg/mL of [USP Metronidazole RS](#) and 0.6 µg/mL of [USP Tinidazole Related Compound A RS](#) in *Solution A*

Standard solution: 30 µg/mL of [USP Metronidazole RS](#) in *Solution A*

Sample stock solution: Nominally 300 µg/mL of metronidazole in *Solution A* prepared as follows. Transfer a portion of Gel to a suitable volumetric flask. Add *Solution A* equivalent to 50% of the flask volume and sonicate or vortex until dissolved. Dilute with *Solution A* to volume. [NOTE—On the basis of formulation, if necessary, centrifuge a portion of the solution at 3000 rpm for 10 min and pass a portion of the supernatant through a filter of 0.45-µm pore size. Use the filtrate.]

Sample solution: Nominally 30 µg/mL of metronidazole in *Solution A* prepared from the *Sample stock solution*

Chromatographic system
(See [Chromatography \(621\)](#), [System Suitability](#).)

- Mode:** LC
- Detector:** UV 319 nm. For *Identification test A*, use a diode-array detector in the range of 210–500 nm.
- Column:** 4.6-mm × 15-cm; 5-µm packing L7
- Column temperature:** 30°
- Flow rate:** 1 mL/min
- Injection volume:** 30 µL

System suitability
Samples: *System suitability solution* and *Standard solution*
[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between metronidazole and tinidazole related compound A, *System suitability solution*

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of metronidazole ($C_6H_9N_3O_3$) in the portion of Gel taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of metronidazole from the *Sample solution*

r_S = peak response of metronidazole from the *Standard solution*

C_S = concentration of [USP Metronidazole RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of metronidazole in the *Sample solution* (µg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

• ORGANIC IMPURITIES

Solution A, Solution B, Mobile phase, and Chromatographic system: Proceed as directed in the Assay.

Standard solution: Use the *System suitability solution* from the Assay.

Sample solution: Use the *Sample stock solution* from the Assay.

System suitability

Sample: *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between metronidazole and tinidazole related compound A

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of tinidazole related compound A in the portion of Gel taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of tinidazole related compound A from the *Sample solution*

r_S = peak response of tinidazole related compound A from the *Standard solution*

C_S = concentration of [USP Tinidazole Related Compound A RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of metronidazole in the *Sample solution* (µg/mL)

Calculate the percentage of each individual unspecified impurity in the portion of Gel taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each unspecified impurity from the *Sample solution*

r_S = peak response of metronidazole from the *Standard solution*

C_S = concentration of [USP Metronidazole RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of metronidazole in the *Sample solution* (µg/mL)

Acceptance criteria: See [Table 2](#).

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Tinidazole related compound A	0.76	0.2
Metronidazole	1.0	—
Any individual unspecified impurity	—	0.3
Total impurities	—	1.0

PERFORMANCE TESTS

- **MINIMUM FILL (755):** Meets the requirements

SPECIFIC TESTS

- **pH (791):** The apparent pH determined potentiometrically is between 4.0 and 6.5.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in laminated collapsible tubes at controlled room temperature.

- **USP REFERENCE STANDARDS (11).**

USP Metronidazole RS

USP Tinidazole Related Compound A RS

2-Methyl-5-nitroimidazole.

$C_4H_5N_3O_2$ 127.10

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METRONIDAZOLE GEL	Documentary Standards Support	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(4)

Current DocID: GUID-B01D3BC7-9A68-4A88-80AC-BE965F2F6B78_1_en-US

DOI: https://doi.org/10.31003/USPNF_M53673_01_01

DOI ref: [b2dam](#)